Clinical characteristics of the HPFS and PHS stratified by lowest tristetraprolin quartile
| TristetraprolinLow (n = 101) | TristetraprolinHigh (n = 303) | P value | |
|---|---|---|---|
| Cohort, n (%) | 0.55 | ||
| HPFS | 66(26) | 188(74) | |
| PHS | 35(23) | 115(77) | |
| Age at diagnosis, median (SD; range) | 67.9 (7.0; 47–81) | 65.0 (6.2; 49–79) | 0.003 |
| Pathologic RP Gleason score, n (%) | <0.001 | ||
| 2–6 | 10 (18) | 47 (82) | |
| 7 | 49 (20) | 192 (80) | |
| 8 | 13 (30) | 30 (70) | |
| 9–10 | 29 (46) | 34 (54) | |
| Clinical stage, n (%) | 0.001 | ||
| T1/T2 | 78 (22) | 272 (78) | |
| T3 | 7 (26) | 20 (74) | |
| T4 | 12 (60) | 8 (40) | |
| Total PSA at diagnosis, ng/mL, n (%) | 0.11 | ||
| 0–4 | 4 (10) | 37 (90) | |
| 4–10 | 37 (19) | 159 (81) | |
| 10–20 | 16 (25) | 47 (75) | |
| >20 | 12 (29) | 29 (71) | |
| Not available | 32 (51) | 31 (49) | |
| Case status (%) | <0.001 | ||
| Lethal | 49 (43) | 64 (57) | |
| Indolent | 52 (18) | 239 (82) |
Abbreviation: RP, radical prostatectomy.